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http://dx.doi.org/10.1016/j.pedneo.2Aim: We aimed to define the etiologic and prognostic factors in live-born infants with hydrops
fetalis (HF) in our tertiary neonatal intensive care unit over a 10-year period.
Methods: Medical records of newborn infants with HF during 2002e2011 were reviewed retro-
spectively. Demographic data, prenatal interventions, clinical and laboratory findings, out-
comes, and the results of postmortem examinations were analyzed.
Results: During the study period, 62 newborn infantswithHFwere identified from16,200 live-born
deliveries and the incidence of HF was 3.8/1000 live births in our hospital. Twenty-eight infants
(45.2%) had immune HF, whereas 34 (54.8%) had nonimmune HF. An etiologic factor could be iden-
tified in 24 (70.5%) infants with nonimmune HF. Lymphatic dysplasias comprised the majority
(23.5%) of the infantswith nonimmuneHF. Mortality ratewas 50%. The presence of two ormore se-
rous cavity effusions and gestational age were independently associated with the risk ofmortality.
Conclusion: Despite the improvements in neonatal care, mortality rate in infants with HF is still
high. Gestational age and the extent of serous cavity determine the risk of mortality. Timely and
advanced prenatal or postnatal new therapeutic strategies may alter this fatal outcome in appro-
priate patients.
Copyright ª 2013, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Hydrops fetalis (HF) is excessive fluid accumulation in fetal
extravascular compartments and body cavities leading toUniversity Ihsan Dogramaci
kara, Turkey.
(S. Takci).
an Pediatric Association. Publish
013.07.008edema, ascites, pleural and pericardial effusions, and
anasarca. HF can be mainly categorized as of immune and
nonimmune causes, but with the decline of rhesus iso-
immunization, most cases have nonimmune etiology. It is
estimated that approximately 76e87% of all cases of HF are
of nonimmune origin.1
Nonimmune HF (NIHF) has a multifactorial cause, con-
sisting of maternal, placental, and fetal pathologies. Theed by Elsevier Taiwan LLC. All rights reserved.
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abnormal fluid transportation between plasma and tissues.
The primary causes of the modification of the distribution
of body fluids are an increase in hydrostatic capillary
pressure and capillary permeability and a reduction of the
plasma osmotic pressure or lymphatic flow.2
The diagnosis and management of HF have improved in
recent years with advances in prenatal diagnostic and
therapeutic interventions together with the advances in
neonatal intensive care. However, HF is still associated with
a high mortality rate.3,4 In the literature, there are limited
data about prognostic factors in newborn infants with HF
and these include some perinatal interventions and some
demographic and clinical features.5e8
In this study we aimed to define the etiologic factors,
and short-term outcome of newborn infants with HF and
identify predictors of mortality in a single tertiary unit over
a 10-year period.
2. Materials and Methods
We performed a retrospective hospital chart review of all
live-born cases with HF delivered at Hacettepe University
Hospital and admitted to the Neonatal Intensive Care Unit
(NICU) of Hacettepe University Ihsan Dogramaci Children’s
Hospital (Ankara, Turkey) during the 2002e2011 period.
The study was approved by the Institutional Ethics Com-
mittee. Live-born infants who died in the first minutes of
life in the delivery room despite neonatal resuscitation
were not included in the study. HF was defined as gener-
alized skin edema with serous effusion in one or more fetal
body cavity. The diagnosis of immune HF (IHF) was based on
clinical and laboratory findings (maternal and fetal blood
group, direct and indirect Coombs test). Maternal and ob-
stetric diseases, prenatal diagnostic and therapeutic in-
terventions, gestational age, birth weight, mode of
delivery, Apgar score at fifth minute, delivery room in-
terventions, postnatal therapies including mechanical
ventilation and surfactant therapy, the etiology of HF, and
mortality were recorded in each infant. If available, post-
mortem examination results were also recorded.
Amniocentesis is needed to perform fetal karyotyping,
amniotic fluid culturing, testing for CMV infections,
assessment of a-fetoprotein levels, testing for thalassemia,
and determination of the lecithin-sphingomyelin ratio.
Prenatal hydrops signs and fetal anemia (hematocrit <30%)
constitute an indication for intrauterine blood transfusion.
Middle cerebral artery peak velocity is also used to assess
fetal anemia (cut-off level 1.5 multiples of the median).
Repeated transfusions were performed considering the
need for fetus within every 3e5 weeks. Pleural effusions
were managed with fetal thoracentesis. Fetal ascites was
treated with in-utero paracentesis and peritoneal-amniotic
shunting. The severity, duration, and persistence of the
pathology determined the procedures used. The indication
of maternal digitalization was fetal supraventricular
tachycardia.
All infants with HF underwent a diagnostic flow chart
according to our NICU protocol. Prenatal and postnatal ul-
trasonographic examinations were performed on all in-
fants. All infants with HF received echocardiography. Fetal
or neonatal karyotyping was offered in all cases of NIHF.The presence of lymphatic dysplasia was evaluated by
microscopic and biochemical investigation (lipid profile) of
ascites, pleural, or pericardial fluids. In addition, magnetic
resonance imagining or computerized tomography was
performed to establish lymphatic malformations in selected
cases. Hematologic disorders were evaluated by complete
blood count, peripheral blood or bone marrow smear,
Coombs test, blood group, hemoglobin electrophoresis, and
KleihauereBetke stain. Inherited metabolic diseases were
evaluated with blood and urine amino acid analysis, urine
organic acid analysis, lysosomal enzyme activities, bone
marrow aspiration and, if necessary, specific enzyme ac-
tivity or genetic analysis. Macroscopic and microscopic
(standard or immunohistochemical staining) examinations
were performed for placental anomalies. All infants were
screened for intrauterine infections such as toxoplasmosis,
rubella, cytomegalovirus, herpes simplex, parvovirus, and
syphilis. Complete and partial postmortem examinations
were offered where relevant.
Statistical data were analyzed by using SPSS version 16.0
software (SPSS Inc., Chicago, IL, USA) on a personal com-
puter. Data was expressed as percentage or mean  stan-
dard deviation. Continuous variables were compared by
two-tailed t test for parametrically distributed data or
ManneWhitney test for nonparametrically distributed data.
Categorical variables were analyzed by c2 test or Fisher
exact test. All the variables significantly associated with
mortality were included in the stepwise multiple logistic
regression models to determine the independent prognostic
study variables. The results are presented by odds ratio and
95% confidence intervals. A p-value of <0.05 was accepted
as statistically significant.
3. Results
During the study period, 62 cases of HF from 16,200 live
born infants were identified in our hospital and the inci-
dence of HF was 3.8/1000 live births, whereas the inci-
dence of NIHF was 2/1000 live births. Mean gestational age
was 33.1  2.9 weeks (27.0e39.0 weeks) whereas mean
birth weight was 2350  640 g (940e3370 g). Prenatal di-
agnoses were available in 35 (56.5%) infants and the most
frequent (25, 40.3%) prenatal diagnostic and therapeutic
intervention was cordocentesis þ blood transfusion. The
mean number of intrauterine transfusions was 2.2  1.8
(1e5). Forty-five (72.6%) infants had aggressive resuscita-
tion at birth and 31 (50.0%) received urgent thoracentesis
or paracenthesis at birth. Fifty-five (88.7%) infants needed
mechanical ventilation during NICU stay. Mortality rate was
50.0%. Demographic and clinical characteristics of infants
with HF are shown in Table 1.
Twenty-eight (45.2%) infants had IHF, whereas 34 (54.8%)
had NIHF. Rh isoimmunization was diagnosed based on
maternal and fetaleneonatal Rh status and positive
maternal, neonatal coombs tests within the presence of
hemolysis. Of 28 infants with IHF, only one infant was
diagnosed with Kell isoimmunization whose Kell antigen
was positive and whose mother was negative within the
positive maternal indirect Coombs test.
Among the infants with NIHF a plausible cause could be
found in 24 (70.5%) infants. Lymphatic dysplasia was the
most common (12.9%) identifiable underlying cause in all
Table 1 Demographic and clinical characteristics of in-
fants with hydrops fetalis (n Z 62).
Demographic and clinical characteristics
Sex (M/F) 33/29 (53.2/46.8)
Gestational age (wk) 33.1  2.9
(27.0e39.0)
Birth weight (g) 2350  640
(940e3370)
Consanguineous parents 15 (24.2)
Prenatal steroids 25 (40.3)
Prenatal diagnosis 35 (56.5)
Prenatal diagnostic and therapeutic
procedures
Amniocentesis 9 (14.5)
Chorionic villus sampling d
Cordocentesis þ blood transfusion 25 (40.3)
Cordocentesis 2 (3.2)
Thoracentesis 4 (6.5)
Paracentesis 4 (6.5)
Maternal digitalization 1 (1.6)
Mode of birth (vaginal/CS) 9/53 (14.5/85.5)
Apgar score (5 min) 5.7  2.3 (2e10)
Aggressive resuscitation at birth
(PPV  CC  Drug)
45 (72.6)
Affected compartments in
hydrops fetalis*
62 (100.0)
Skin and subcutaneous tissue 34 (54.8)
Pleural effusion 12 (19.4)
Pericardial effusion 54 (87.1)
Ascites 30 (48.4)
Two or more serous cavity effusions
Thoracentesis and/or paracentesis
at birth
31 (50.0)
Hypoxic respiratory failure (OI >14) 24 (38.7)
Need for mechanical ventilation 55 (88.7)
Need for HFOV treatment 17 (27.1)
Need for surfactant therapy 28 (45.2)
Need for inhaled NO therapy 3 (4.8)
Pneumothorax 13 (21.0)
Duration of mechanical ventilation
(day)
3.0 (0e38)
Duration of hospitalization (day) 8.5 (0.5e80)
Mortality 31 (50.0)
Postmortem examination (partial or
whole autopsy)
14 (45.2)
Data are presented as n (%), mean  SD (range), or median
(range).
CC Z cardiac compression; CS Z cesarean section;
HFOV Z high frequency oscillatory ventilation; NO Z nitric
oxide; OI Z oxygenation index; PPV Z positive pressure
ventilation; SD Z standard deviation.
* More than one compartment can be affected in each infant.
Table 2 Type and etiology of hydrops fetalis (n Z 62).
n (%)
Immune 28 (45.2)
Rh-isoimmunization 27 (43.5)
Anti-Kell isoimmunization 1 (1.6)
Nonimmune 34 (54.8)
Cardiovascular diseases 4 (6.5)
Hypertrophic cardiomyopathy 1 (1.6)
Non-compaction cardiomyopathy 1 (1.6)
Ebstein anomaly 1 (1.6)
Supraventricular tachycardia 1 (1.6)
Lymphatic dysplasia 8 (12.9)
Chylothorax 3 (4.8)
Chylous ascites 3 (4.8)
Lymphangioma 2 (3.2)
Hematologic diseases 3 (4.8)
Congenital dyserythropoietic anemia 2 (3.2)
Hereditary spherocytosis þ hemophagocytosis 1 (1.6)
Inborn errors of metabolism 3 (4.8)
Nieman Pick Type C disease 1 (1.6)
Gangliosidosis 1 (1.6)
Zellweger syndrome 1 (1.6)
Placental disorders 3 (4.8)
Twin-to-twin transfusion syndrome 1 (1.6)
Placental hemangioma 1 (1.6)
Placental thrombosis and chorioangioma 1 (1.6)
Infections 1 (1.6)
Congenital CMV infection 1 (1.6)
Others 2 (1.6)
Trisomy 21 þ myelodysplastic syndrome 1 (1.6)
Sacrococcygeal teratoma 1 (1.6)
Undefined etiology 10 (16.1)
CMV Z cytomegalovirus; Rh Z rhesus.
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rable between infants with IHF and NIHF (42.9% vs. 55.9%
respectively, p >0.05). In the infants with lymphatic
dysplasia (nZ 8) only one infant died, with a mortality rate
of 12.5%.
In comparing infants who survived and died, mean
gestational age and birth weight of infants who died weresignificantly lower than infants who survived (p <0.01 and p
<0.05 respectively) and they needed more neonatal
resuscitation at birth (p <0.001), as expected. In accor-
dance with this, the frequency of two or more serous cavity
effusions was significantly higher in infants who died (p
<0.001). Infants who died needed more surfactant therapy
during NICU stay (p <0.001; Table 3).
Type of delivery, sex, prenatal steroids, and presence of
pericardial effusions and pneumothorax during follow-up
did not influence the outcome (p >0.05). Factors associ-
ated with mortality were younger gestational age, lower
birth weight, lower Apgar score at 5 minutes, aggressive
resuscitation at birth, presence of pleural effusions, asci-
tes, presence of two or more serious cavity effusions, the
need for surfactant treatment, and mechanical ventilation
(Table 3). However, by stepwise multiple logistic regression
analysis, gestational age and the presence of two or more
serous cavity effusions was associated independently with
mortality (Table 4).
The median average duration of follow-up was 8.5 days
(range, 0.5e80 days) in all HF cases whereas it was 3 days
(range, 0.5e35 days) in nonsurvivors and 20 days (range,
8e80 days) in survivors up to discharge. Postmortem ex-
aminations were performed in 11 of 16 non-surviving infants
with NIHF. This led to exact diagnosis in three cases
Table 3 Comparison of the clinical and demographic characteristics of infants with hydrops fetalis who died or survived.
Demographic and clinical characteristics Infants who survived (n Z 31) Infants who died (n Z 31) p
Gestational age (wk) 34.2  2.8 (27.0e39.0) 32.1  2.8 (27.4e38.0) 0.005
Birth weight (g) 2543  511 (1670e3300) 2156  702 (940e3370) 0.016
Apgar score (5 min) 7.1  1.9 (3e10) 4.4  1.7 (2e8) 0.000
Aggressive resuscitation at birth 16 (51.6) 29 (93.5) 0.000
Type of hydrops fetalis
Immune 12 (38.7) 16 (51.6) 0.307
Nonimmune 19 (61.3) 15 (48.4) 0.444
Affected compartments in hydrops fetalis
Skin and subcutaneous tissue 31 (100.0) 31 (100.0) 1.000
Pleural effusion 12 (38.7) 22 (71.0) 0.011
Pericardial effusion 3 (9.7) 9 (29.0) 0.106
Ascites 23 (74.2) 31 (100.0) 0.005
Two or more serous cavity effusions 6 (19.3) 24 (77.4) 0.000
Prenatal diagnostic and therapeutic procedures
Amniocentesis 6 (19.4) 3 (9.7) 0.473
Cordocentesis þ blood transfusion 13 (41.9) 12 (38.7) 0.710
Cordocentesis 1 (3.2) 1 (3.2) 1.000
Thoracentesis 2 (6.5) 2 (6.5) 1.000
Paracentesis 1 (3.2) 2 (6.5) 0.550
Maternal digitalization 1 (3.2) 0 (0) d
Thoraparacentesis and/or blood transfusion at birth 8 (25.8) 23 (74.2) 0.000
Hypoxic respiratory failure (OI >14) 11 (35.5) 13 (41.9) 0.602
Need for mechanical ventilation 24 (77.4) 31 (100.0) 0.011
Need for HFOV treatment 11 (35) 6 (19.4) 0.255
Need for surfactant therapy 6 (19.4) 22 (71.0) 0.000
Pneumothorax 4 (12.9) 9 (29.0) 0.211
Data are presented as n (%) or mean  SD (range).
HFOV Z high frequency oscillatory ventilation; OI Z oxygenation index; SD Z standard deviation.
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disease, congenital CMV infection) and the confirmation of
the diagnoses in three cases (Down syndrome-associated
myelodysplastic syndrome and congenital dyserythropoietic
anemia in two cases).
4. Discussion
In recent years, most newborn infants with HF were clas-
sified as NIHF as the proportion of infants with IHF
decreased to 10% due to the use of anti-D immunoglobulin
prophylaxis, intrauterine transfusions, and close follow-up
of the pregnancies with Rh-isoimmunization in developed
countries.3 However, in developing countries the incidence
of IHF is still high, as also reflected by our results.9 In ourTable 4 Stepwise multiple logistic regression analysis of
predictive factors for poor outcome in hydrops fetalis.
Adjusted
odds
ratio
95% confidence
interval
p
Gestational age 0.63 0.44e0.89 0.009
Two or more serous
cavity effusions
12.9 2.4e70.9 0.003
Need for surfactant 0.22 0.04e1.12 0.069study, nearly half of the cases (45.2%) had IHF. Our hospital
is a tertiary level perinatal center for high-risk pregnancies
and many pregnancies with Rh isoimmunization are
referred from rural regions of Turkey. Unfortunately, most
of these patients are usually referred in the advanced pe-
riods of pregnancy, which makes therapeutic interventions
less effective. In the literature, the incidence of NIHF
varies widely from 0.3/1000 to 2.4/1000 live births.10,11 In
this study, we found a high incidence of NIHF (2/1000) in
our hospital as it is a referral center for high-risk
pregnancies.
The most common diagnosis associated with NIHF was
lymphatic dysplasia in this study. The prognosis was favor-
able in eight infants in this group of etiology because there
was only one death. Of the eight infants, seven were
diagnosed with chylothorax and chylous ascites. The
symptoms rapidly resolved with the drainage of the accu-
mulated fluid by thoracentesis or paracentesis, enteral
nutrition with medium chained triglycerides, and soma-
tostatine analogues after birth. In the literature, in a large
multicenter study by Abrams et al,3 the lowest mortality
rate was found among infants with congenital chylothorax
(5.9%).
In our study population, congenital heart diseases
constituted the second most common cause of NIHF. In a
systemic review of 5437 NIHF cases, congenital cardiovas-
cular diseases were reported as the most frequent etiologic
factor by a ratio of 21.7%.1
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account for 1e2% of all NIHF cases.1 However, in our study
9% of infants with NIHF had inborn errors of metabolism and
we think this was the result of a high incidence of
consanguineous marriages in Turkey.
The percentage of idiopathic cases in NIHF reported in
the literature is 4e60%, depending primarily on the diag-
nostic methods available in each service.3,12,13 In our study,
the ratio of infants with idiopathic NIHF was approximately
30%. Besides limited sophisticated diagnostic procedures,
one of the explanations for this high incidence of idiopathic
cases may be that it is the result of the limited time for the
establishment of the exact diagnosis as most of the infants
with NIHF died in the first week of life. Also, performing
postmortem examinations is important for the establish-
ment of an exact diagnosis.14 In the study by Rodrı´guez
et al12 the cause of HF was confirmed at a rate of 92% in 51
still-born fetuses. In our study, the diagnosis of six infants
(55%) was achieved with a postmortem examination.
Various antenatal and postnatal indicators of prognosis
have been described in infants with HF.4e8,15 These are
prenatal diagnosis of HF, gestational age at delivery, 1st
minute and 5th minute Apgar scores, intubation and chest
compression in the delivery room, low serum albumin
concentration, two or more serous cavity effusions, the
presence of pleural effusion, and need for thoracentesis.
Gestational age at delivery was found to be a prognostic
factor in a number of recently published studies.15,16 About
30 years ago, early delivery was suggested to be a favorable
factor for the survival of the fetus with HF.17 However, in a
large multicenter study, association between prematurity
and poor outcome has been shown clearly.3 We think that
preterm delivery reflects the severity of HF and that pre-
maturity brings an additional burden by its complications
such as respiratory distress syndrome to the management of
HF. Tocolytic therapy and close monitoring to prolong
pregnancy in selected patients might improve the survival.
However, administration of antenatal steroids did not in-
fluence survival in the present study, which is in line with
previous reports.4,18
Poor response to neonatal resuscitation at birth has been
shown to be associated with mortality in previous re-
ports.4,15 In our study, fatal cases required significantly
more aggressive resuscitation at birth and they had lower
Apgar scores.
In our study, by stepwise multivariate analysis of all risk
factors, gestational age, and presence of two or more se-
rous cavity effusions was found to be the strongest pre-
dictor of mortality. This result was similar to previous
reports.8,18 Pleural effusion develops with a compression of
the heart and obstruction of the venous return and causes
pulmonary hypoplasia leading to respiratory distress soon
after birth. It has been shown that in utero decompression
of hydrothorax may reverse fetal distress and this proce-
dure could give time for the delivery of uncompromised
infants.19 Also, a detailed review of the literature indicates
that pleural drainage in utero may improve outcome in
fetuses with persistent effusions.20 These prenatal in-
terventions include thoracentesis, thoracoamniotic shunt-
ing, and pleurodesis. It was suggested that thoracentesis is
of limited value and pleural fluid accumulates 1e7 days
after the procedure. Therefore, it was concluded thatthoracoamniotic shunting may improve the survival rate
especially in fetuses whose effusion rapidly reac-
cumulates.7 We did not perform thoracoamniotic shunting
in any of the infants. Of four infants who required thor-
acentesis, two died. We feel that it is not accurate to the
judge outcome of thoracentesis due to the small case
series.
In our study, outcome was not satisfactory in infants who
were treated with surfactant and mechanical ventilation.
Surfactant was used in infants whose clinical pictures were
complicated with respiratory distress syndrome or who
were thought to have pulmonary hypoplasia.
In conclusion, there is strong association between
gestational age, the presence of two or more serous cavity
effusions, and poor outcome in infants with HF. There-
fore, severity of hydrops is the main predictor for mor-
tality. Despite improvements in postnatal care such as
advanced mechanical ventilation, surfactant treatment,
and inhaled nitric oxide, mortality rates are still high in
infants with HF.Conflicts of Interest
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